MGX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
2.2M
+949.8%
-257000
-120.6%
1.2M
-68.1%
3.9M
-54.8%
8.7M
Cost of Revenue
0
0
0
0
0
Gross Profit
2.2M
+949.8%
-257000
-120.6%
1.2M
-68.1%
3.9M
-54.8%
8.7M
Operating Expenses
24.4M
-14.4%
28.5M
+10.4%
25.8M
-8.6%
28.3M
-10.2%
31.5M
R&D
17.5M
-22.1%
22.5M
+16.6%
19.3M
-10.2%
21.5M
-15.0%
25.3M
SG&A
6.9M
+14.6%
6.0M
-8.1%
6.5M
-3.6%
6.8M
+9.0%
6.2M
Operating Income
-22226000
+22.8%
-28773000
-17.0%
-24587000
-0.9%
-24367000
-6.7%
-22839000
EBITDA
-20972000
+23.8%
-27508000
-18.0%
-23312000
-1.1%
-23067000
-7.2%
-21515000
Net Income
-21126000
+23.1%
-27482000
-19.2%
-23059000
-2.4%
-22528000
-10.5%
-20393000
EPS (Basic)
$-0.56
+23.3%
$-0.73
-19.7%
$-0.61
-1.7%
$-0.60
-9.1%
$-0.55
EPS (Diluted)
$-0.56
+23.3%
$-0.73
-19.7%
$-0.61
-1.7%
$-0.60
-9.1%
$-0.55
Shares (Diluted)
37.8M
+0.3%
37.7M
+0.2%
37.6M
+0.3%
37.5M
+0.3%
37.3M
Metagenomi Therapeutics (MGX) — Financials